DANIEL ZAWITOSKI

TIBER CREEK GROUP · Washington, DC · registered since 2024

Registered · LDAActive

Send proposal →Contact →Claim this profile →

At a glance

Registered since

2024

Senate LDA system

Clients

last 3 years

Filings

6 agencies contacted

Activity

filings by quarter

Works on

Health Issues 23 Medicare/Medicaid 15 Budget/Appropriations 10 Energy/Nuclear 9 Homeland Security 7 Environment/Superfund 6 Taxation/Internal Revenue Code 6 Computer Industry 6 Trade (domestic/foreign) 6 Aviation/Airlines/Airports 3 Consumer Issues/Safety/Products 3 Manufacturing 3 Science/Technology 3 Telecommunications 3 Communications/Broadcasting/Radio/TV 2 Defense 1 Financial Institutions/Investments/Securities 1

Background

Government experience

Chief of Staff

Rep. Scott Peters (2018-2023); Legislative Director, Rep. Scott Peters (2015-2018); Legislative Assistant, Rep. Scott Peters (2014-2015); Legislative Correspondent, Rep. Scott Peters (2013-2014).

Disclosed on LD-2 filings

Chief of Staff

Rep. Scott Peters

2018-2023); Legislative Director, Rep. Scott Peters (2015-2018); Legislative Assistant, Rep. Scott Peters (2014-2015); Legislative Correspondent, Rep. Scott Peters (2013-2014

Disclosed on LD-2 filings

Career

TIBER CREEK GROUP

Washington, DC

2024 - present

Specific issues

Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing).

Medicare/Medicaid · 2024 Q3

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA, Consolidated Appropriations Act, 2023 (PL 117-328).

Health Issues · 2024 Q3

Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Investment Tax Credit (ITC).

Taxation/Internal Revenue Code · 2024 Q3

Funding for clean energy programs.

Budget/Appropriations · 2024 Q3

Issues related to permanently removing carbon from the atmosphere; S.1576 - CREST Act of 2023; S.2002 - CREATE Act of 2023.

Energy/Nuclear · 2024 Q3

Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to the Medicaid Drug Rebate Program (MDRP); H.R.5539/S.3131 - ORPHAN Cures Act.

Medicare/Medicaid · 2024 Q3